Overview

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
6-Mercaptopurine
Asparaginase
Cortisol succinate
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Mercaptopurine
Mitoxantrone
Prednisone
Vincristine